Estland - Estlands - Ravimiamet

medochemie limited - metformiin+sitagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 180tk; 850mg+50mg 28tk; 0+50mg 14tk; 850mg+50mg 112tk; 850mg+50mg 30tk

Europese Unie - Estlands - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformiin vesinikkloriid - suhkurtõbi, tüüp 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Europese Unie - Estlands - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformiin vesinikkloriid - suhkurtõbi, tüüp 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 erinevate kombinatsioonide kohta kättesaadavate andmete osas).

Europese Unie - Estlands - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptin, metformiin vesinikkloriid - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Estland - Estlands - Ravimiamet

medochemie limited - metformiin+vildagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 60tk; 850mg+50mg 180tk; 850mg+50mg 30tk; 850mg+50mg 10tk

Estland - Estlands - Ravimiamet

sandoz pharmaceuticals d.d. - metformiin+vildagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 30tk

Estland - Estlands - Ravimiamet

teva b.v. - metformiin+vildagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 12tk; 850mg+50mg 60tk; 850mg+50mg 30tk

Estland - Estlands - Ravimiamet

teva b.v. - metformiin+vildagliptiin - õhukese polümeerikattega tablett - 1000mg+50mg 12tk; 1000mg+50mg 60tk

Estland - Estlands - Ravimiamet

sandoz pharmaceuticals d.d. - metformiin+vildagliptiin - õhukese polümeerikattega tablett - 1000mg+50mg 60tk; 1000mg+50mg 30tk

Estland - Estlands - Ravimiamet

sandoz pharmaceuticals d.d. - sitagliptiin - õhukese polümeerikattega tablett - 50mg 50tk; 50mg 28tk